Lumenis Introduces Stellar M22™

Stellar M22™ is Now available in the USA and Europe

Lumenis, the inventor of IPL, is proud to introduce the next generation in Multi-Application platforms, The Stellar M22™. This system offers everything users need in one platform, while making both the physician and patient experience more seamless and successful than ever before.

Lumenis notes the launch continues Lumenis’ mission to improve the standard of care in the ever-growing, multi-billion-dollar energy-based skincare market.

“Lumenis is the pioneer in IPL, from the PhotoDerm to the M22, all of which were and are the gold standard,” said Dr. Mitchel Goldman from San Diego, California. “The Stellar M22’s efficiency is second-to-none with improved patient comfort, speed, versatility, reliability and results with better outcomes. At the end of the day, we offer patients treatments that work, which translates into increased patient satisfaction and increased profitability,” continued Dr. Goldman.

The Stellar M22 is built and based upon the gold standard of Lumenis’ original M22, and continues to carry out all treatment capabilities (i.e. treatment of vascular lesions, skin texture, tone, and hair removal) but with upgrades that make for a further amplified experience.

“The new Stellar M22™ IPL allows for easy and quick treatment with the great output and efficacy we already know from Lumenis,” said Dr. Tretti Clementoni, from Milan, Italy. He continued, “It is a huge time saver and the results are stellar!”

The latest leaps of the sixth generation IPL, Stellar M22™ include a dramatically improved user interface with a larger screen that enables a faster treatment time and more comfortable viewing from a distance. In addition, the Stellar M22™ provides a new ergonomic IPL hand piece design and longer SapphireCool™ Lightguides for better visibility of the treatment area.

“Lumenis is thrilled to introduce the new Stellar M22™, our next-generation in multi-application devices, enabling treatment of over 30 skin conditions and hair removal across skin type, gender and age,” said Tzipi Ozer-Armon, CEO of Lumenis. “Like the M22 before it, Stellar redefines the benchmark in the category and demonstrates our continued commitment to innovation and better technology for better patient care.”

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version